Polyphor launches the development of an inhaled antibiotic murepavadin
Polyphor Ltd has announced the development of an inhaled dosage form of its breakthrough antibiotic Murepavadin. Continue reading New Inhaled Antibiotic To Treat Respiratory Infections
Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™
1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Continue reading New Pre-Clinical Data for Iclaprim
CARB-X has awarded $8.9M (€7.6M) to Antabio for the development of a new antibiotic against resistant Pseudomonas infections in cystic fibrosis patients.
Antabio is a French company developing new antibiotics to fight the rapidly Continue reading French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic